Natco Pharma ties up with Gilead

NatcoAccording to a press release Natco Pharma Limited has signed a licensing deal with Gilead Sciences Inc to make and sell generic versions of the US drugmaker’s chronic hepatitis C medicines.
Drugs under the deal include sofosbuvir, a combination of ledipasvir and sofosbuvir, and GS-5816, which is in late-stage clinical trials, Natco said in a release.
Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top